Growing evidence suggests that TLR4 signaling could act as an ideal target to improve the effectiveness of immunotherapy in HCC, reshaping the immune TME, and potentiating the secretion of various chemokines with anti-tumor activity. The gene discussed is TLR4; the disease is neoplasm.